Study start date
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB2-IVA - Planned for radical radiotherapy and concurrent cisplatin chemotherapy. - Able to receive weekly cisplatin. - No prior anticancer treatment for cervical cancer - ECOG 0 or 1 - Life expectancy of greater than 3 months. - Normal organ and marrow function - Able to take oral medications. - Ability to understand and willing to sign the consent form - Willing to undergo biopsies of cervical tumor.
- Evidence of distant metastases - Receiving any other investigational agents concurrently or within 4 weeks. - Known diabetes mellitus. - Currently taking metformin, sulfonylureas, thiazolidinediones or insulin. - History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or cisplatin. - Any condition associated with increased risk of metformin-associated lactic acidosis - Uncontrolled inter-current illness - Pregnant women - History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for >=5 years. - Known HIV-positive - History of bowel obstruction or malabsorption syndromes - History of active clinically significant bleeding - Contraindications to radiotherapy - Taking drug disulfiram (antabuse).